Related Experiment Videos
Treatment of hepatitis B
1Division of Gastroenterology and Hepatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, USA.
Insights
Hepatitis B virus (HBV) infection can lead to chronic liver disease and cancer. Current treatments like interferon alfa and lamivudine aim to suppress viral replication but have limitations.
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Background:
- Hepatitis B virus (HBV) is a significant global health concern, frequently causing cirrhosis and hepatocellular carcinoma.
- The progression of HBV infection is influenced by factors such as the age of acquisition and viral markers like hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and HBV DNA levels.
- Chronic HBV infection is defined by persistent elevation of alanine aminotransferase (ALT) and the presence of HBsAg for over six months, indicating active viral replication.
Purpose of the Study:
- To outline the management of chronic active Hepatitis B virus infection.
- To discuss the therapeutic goals, including viral replication suppression and viral clearance.
- To review the efficacy and side effect profiles of available treatments: interferon alfa and lamivudine.
Main Methods:
- Review of current medical literature on Hepatitis B virus infection and its treatment.
- Analysis of clinical data regarding the effectiveness and adverse events associated with interferon alfa and lamivudine therapies.
- Identification of treatment endpoints, such as normalization of ALT levels and elimination of HBeAg and HBV DNA.
Main Results:
- Interferon alfa demonstrates efficacy in 25%–40% of patients but is associated with significant side effects.
- Lamivudine achieves similar efficacy rates (25%–40%) with a more favorable side effect profile.
- A key limitation of lamivudine is the potential for viral mutations and the development of drug-resistant HBV strains.
Conclusions:
- Treatment for chronic active HBV is indicated to control viral load and prevent disease progression.
- Both interferon alfa and lamivudine offer therapeutic benefits but present distinct challenges regarding side effects and drug resistance.
- Further research into novel therapeutic strategies is warranted to overcome the limitations of current HBV treatments.
Abstract:
Hepatitis B virus (HBV) is a major world health problem and a common cause of cirrhosis and hepatocellular carcinoma. The natural history of HBV varies with many factors, including age of acquisition. Persistent elevation of alanine aminotransferase (ALT) levels and presence of hepatitis B surface antigen for > 6 months after infection suggest chronic HBV. Presence of hepatitis B e antigen (HBeAg) and HBV DNA in serum indicate active disease. Treatment is indicated for chronic active HBV. The aim of treatment is to suppress viral replication and eliminate the virus. Endpoints of treatment are normalization of ALT levels and elimination of HBeAg and HBV DNA from the blood. Available treatments are interferon alfa and lamivudine. Interferon is effective in 25% to 40% of patients, but has serious side effects. Lamivudine is effective in a similar percentage of patients and has fewer side effects; however, it is associated with the emergence of viral mutations and drug-resistant strains.